Smith & Nephew

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics; Sports Medicine and ENT; and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies and ENT. The Advanced Wound Management segment comprises advanced wound care, advanced wound bioactives and advanced wound devices businesses. The company was founded by Thomas James Smith in 1856 and is headquartered in Watford, the United Kingdom.

Earnings data Q4 2019

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT. The Advanced Wound Management segment includes advanced wound care, advanced wound bioactives, and advanced wound devices businesses. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.

Shares in Smith & Nephew PLC (LSE:SN) jumped after it was revealed that activist investor Cevian Capital has built a stake in the replacement hip and knee maker.  The Swedish hedge fund, which has previously taken positions in Aviva, Vodafone, Pearson and RSA Insurance, declared a stake of 5.02%.

Smith & Nephew jumps as activist Cevian's stake revealed

AstraZeneca

BAE Systems PLC

British American Tobacco

Diageo

National Grid

Polar Power

RELX

Unilever

Unfortunately, UK investors have had to suffer weak or negative capital gains in recent years to get those high yields. The good news is that the UK remains an attractive market for dividend investors. Don't forget that companies usually retain some of their earnings to fund expansion and growth, so dividends have (on average) grown ahead of inflation over the medium and long term,.

U.K. Top 40 Quality Dividend Stocks: Summer 2024

Smith & Nephew (SNN) announces the launch of its new CORIOGRAPH Pre-Operative Planning and Modeling Services, exclusively for use with the CORI Surgical System.

Smith & Nephew's (SNN) CORIOGRAPH to Aid Arthroplasty Procedure

Smith & Nephew's share price has increased by 14% since September 2022, indicating undervaluation. The company showed decent top line growth with a 6.4% increase in revenue last year. While the company's growth plans are transforming the business, there are concerns about the actual performance and management quality.

Smith & Nephew: Work To Be Done But Still Long-Term Potential

Smith & Nephew plc (NYSE:SNN ) Q1 2024 Sales/Trading Statement Conference Call May 1, 2024 3:30 AM ET Company Participants Deepak Nath - Chief Executive Officer John Rogers - Chief Financial Officer Conference Call Participants Jack Reynolds-Clark - RBC Capital Markets Caitlin Cronin - Canaccord Genuity Hassan Al-Wakeel - Barclays Julien Dormois - Jefferies Veronika Dubajova - Citi Dylan Van Haaftan - Stifel David Adlington - JPMorgan Sezgi Ozener - HSBC Deepak Nath Good morning, and welcome to the Smith & Nephew Q1 2024 Results Presentation. As mentioned, I'm Deepak Nath.

Smith & Nephew plc (SNN) Q1 2024 Sales/Trading Statement Call Transcript

Smith & Nephew jumped to the top of the FTSE 100 as the UK MedTech delivered a confident first-quarter update and reiterated revenues would grow strongly over the remainder of the year. Sales were up by 2.9% on an underlying basis to US$1.39 billion, helped by good performances from orthopaedics (4.4%) and sports medicine (5.5%) with wound management seeing a fall.

Smith & Nephew tops Footsie after bullish sales update

Legal & General Group PLC

The list ranks stocks based on their market cap and dividend yield alone. What I am looking for is quality dividend stocks with long track records of progressive dividend growth, and while dividend yield is still important, it's a secondary consideration.

U.K. Top 40 Quality Dividend Stocks: Q2 2024

The latest partnership allows Smith+Nephew (SNN) to complement its existing implant range with the cutting-edge navigation technology of NAVBIT.

Smith+Nephew (SNN) Expands in Australia With New Alliance

Compact, single-use, and simple-to-use technology offers surgeons a fast, reliable navigation solution for hip arthroplasty Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announced an agreement with NAVBIT to exclusively distribute the NAVBIT SPRINT™ in Australia during the recent Australian Orthopedics Association COE Meeting in Sydney. A single-use, sterile navigation system with everything provided in a small carton, NAVBIT SPRINT™ is designed to suit busy surgeons - and its convenient product format makes it extremely practical and cost efficient for hospitals and day surgery environments.

Smith+Nephew signs exclusive distribution agreement to provide unique NAVBIT SPRINT™ solution in Australia

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the review of medical technologies guidance from the UK National Institute for Health and Care Excellence (NICE) for its PICO Single Use Negative Pressure Wound Therapy System (sNPWT).

Smith+Nephew's PICO™ Single Use Negative Pressure Wound Therapy System provides better clinical outcomes versus standard of care according to UK National Institute for Health and Care Excellence (NICE)

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, is pleased to announce the launch of its RENASYS EDGE Negative Pressure Wound Therapy (NPWT) System in the US as a patient-centric option for treating chronic wounds. The system is lightweight and compact allowing it to be easily carried or worn,1 it features a discreet canister, and operates quietly so as not to draw attention or disturb the patients' daily activities.1

Smith+Nephew introduces the RENASYS™ EDGE Negative Pressure Wound Therapy System – an exciting new option in home-based care for patients living with chronic wounds

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has been named the Preferred Sports Medicine Technology Partner of UFC – the world's premier mixed martial arts organization and one of the foremost global brands in all of sports. Under the terms of the multi-year partnership, Smith+Nephew will activate its brand through UFC's immense global presence to promote the repair, regeneration and recovery of Sports Medicine injuries through advanced technologies.

Smith+Nephew teams up with UFC to be first-ever Preferred Sports Medicine Technology Partner

Becton, Dickinson and Co.

Globus Medical

Intuitive Surgical

Medtronic

Stryker

Zimmer Biomet Hlds

There are some robotic surgery stocks for investors to buy in March this year. The growth of robotic-assisted surgery has been driven by its potential benefits, such as smaller incisions, reduced pain and scarring, quicker recovery times, and improved clinical outcomes.

7 Robotic Surgery Stocks to Buy for the Future of Healthcare

JP Morgan has spotlighted Smith & Nephew PLC (LSE:SN) for its revenue acceleration and margin expansion potential, setting a price target of 1,300p - a 21% premium to the current stock price. Despite investor scepticism, the bank has added S&N to its Analyst Focus List (AFL), highlighting its attractive risk-reward profile in the healthcare sector.

Smith & Nephew: Scepticism has been overplayed, says leading investment bank

Smith & Nephew plc (SNN) Q4 2023 Earnings Call Transcript

Smith & Nephew PLC (LSE:SN) kept its dividend unchanged and guided to solid growth this year as it reported 2023 results in line with improved guidance from last summer. The hip and knee replacement specialist posted results showing $5.55 billion of revenue for the past calendar year, up 7.2% on an underlying basis and 6.4% reported.

Smith & Nephew profits meet targets, 'robust' growth expected in 2024

Sarcos Technology and Robotics Corp

There are some key robotics stocks for investors to buy in February. This is amid the broader indices such as the Nasdaq making a brief pullback.

3 Millionaire-Maker Robotics Stocks to Buy in February 2024

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Are Investors Undervaluing Smith & Nephew SNATS (SNN) Right Now?

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces full commercial availability of its AETOS Shoulder System in the US, along with 510(k) clearance for its use with ATLASPLAN◊ 3D Planning Software and Patient Specific Instrumentation for total shoulder arthroplasty. Total shoulder arthroplasty is one of the fastest growing segments in Orthopaedics with an estimated 250,000 procedures in the US by 2025.1

Smith+Nephew announces commercial launch of its AETOS™ Shoulder System for anatomic and reverse shoulder replacement at AAOS 2024 Annual Meeting

Smith+Nephew (LSE: SN, NYSE:SNN), the global medical technology company, announces it will provide a glimpse into the future at AAOS 2024. With a first opportunity to see a forthcoming new feature* for its CORI◊ Surgical System, this exclusive image-agnostic* robotic-assisted surgical solution is designed to further help personalize surgery, advance efficiencies, and optimize performance across Smith+Nephew's orthopaedic reconstruction portfolio.

Smith+Nephew to showcase leading, innovative AI-driven robotic-assisted solutions for personalized orthopaedic surgery at AAOS 2024 Annual Meeting

12 February 2024 Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces the premiere of its newly acquired CARTIHEAL◊ AGILI-C◊ Cartilage Repair Implant alongside the REGENETEN◊ Bioinductive Implant at the AAOS Annual Meeting, demonstrating its leadership with products that enable biological healing for Sports Medicine. Backed by impressive clinical evidence, both technologies are transforming the way healthcare professionals treat soft tissue repair and helping improve patient outcomes versus the current standard of care.1,2 CARTIHEAL AGILI-C◊ Cartilage Repair Implant – a simple, single surgery to repair cartilage and restore bone The CARTIHEAL AGILI-C implant is an accessible, one-step treatment for osteochondral (bone and cartilage) lesions that does not require donor tissue.

Smith+Nephew unveils expanded Sports Medicine portfolio to enable biological healing at AAOS 2024 Annual Meeting

Is Smith & Nephew SNATS (SNN) Stock Undervalued Right Now?

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces a new report examining musculoskeletal injury care and reimbursement in Australia that urges health payers and providers to resolve system-wide challenges hindering positive patient pathways from primary settings through to recovery.

Australia's approach to musculoskeletal injury care and reimbursement demands rethink: Report

First published randomized controlled trial for market-leading implant demonstrates impressive outcomes for rotator cuff tears

New study confirms Smith+Nephew's REGENETEN™ Bioinductive Implant reduces full-thickness rotator cuff re-tear rates¹ by 68%

Smith & Nephew PLC (LSE:SN) said today that it has closed the acquisition of CartiHeal, an Israel-based developer of sports medicine technology for cartilage regeneration in the knee.  The medical technology company paid US$180 million to complete the deal, with up to a further US$150 million payment contingent on future financial performance.

News for Smith & Nephew Stock (SNN)